With An Eye On China’s Growing PAD Market, SciClone Teams Up With Taiwan Liposome Co.
This article was originally published in PharmAsia News
Executive Summary
Looking to take on Bayer/UCB’s Prostavasin and a local blockbuster from Beijing Tide Pharmaceutical Co., SciClone will jump into China’s peripheral arterial disease market with what it hopes is a differentiated product developed by TLC.